​

Century Therapeutics (IPSC) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

IPSC Stock Forecast

Century Therapeutics (IPSC) stock forecast, based on 9 Wall Street analysts, predicts a 12-month average price target of $3.00, with a high of $4.00 and a low of $2.00. This represents a 20.00% increase from the last price of $2.50.

High: $4 Avg: $3 Low: $2 Last Closed Price: $2.5

IPSC Stock Rating

Century Therapeutics stock's rating consensus is Buy, based on 9 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 7 Buy (77.78%), 2 Hold (22.22%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 9 0 2 7 Strong Sell Sell Hold Buy Strong Buy

IPSC Price Target Upside V Benchmarks

TypeNameUpside
StockCentury Therapeutics20.00%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts122
Avg Price Target$2.00$3.00$3.00
Last Closing Price$2.50$2.50$2.50
Upside/Downside-20.00%20.00%20.00%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Mar, 26131--5
Feb, 26121--4
Jan, 26121--4
Dec, 25121--4
Nov, 2522---4
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Mar 13, 2026Daina GrayboschLeerink Partners$2.00$2.52-20.63%-20.00%
Jan 20, 2026Piper Sandler$4.00$2.1784.33%60.00%
Nov 06, 2024Mitchell KapoorH.C. Wainwright$5.00$1.39259.71%100.00%
Apr 12, 2024Edward TenthoffPiper Sandler$9.00$4.05122.22%260.00%
Jan 05, 2023Edward TenthoffPiper Sandler$14.00$4.84189.26%460.00%
Dec 27, 2022Geulah LivshitsChardan Capital$19.00$5.67235.10%660.00%
Nov 14, 2022H.C. Wainwright$25.00$11.00127.27%900.00%
Apr 29, 2022Leerink Partners$27.00$12.03124.44%980.00%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Mar 13, 2026Leerink PartnersMarket PerformMarket Performhold
Jan 20, 2026Piper SandlerOverweightOverweighthold
Aug 15, 2024H.C. WainwrightBuyBuyhold
Aug 08, 2024Rodman & RenshawBuyinitialise
Jun 17, 2024Piper SandlerOverweightOverweighthold
Jun 04, 2024Piper SandlerBuyBuyhold
Apr 12, 2024Piper SandlerOverweightOverweighthold
Aug 28, 2023NeedhamNeutraldowngrade
Aug 10, 2023Chardan CapitalBuyBuyhold
Jan 06, 2023SVB LeerinkOutperformOutperformhold

Financial Forecast

EPS Forecast

$-6 $-5 $-4 $-3 $-2 $-1 $0 $1 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-2.27$-2.30$-1.61$-0.14---
Avg Forecast$-2.31$-2.17$-1.60$-1.76$-1.50$-2.09$-1.99
High Forecast$-0.18$-1.86$-1.42$-1.43$0.26$0.36$0.34
Low Forecast$-5.20$-2.35$-1.71$-1.99$-3.88$-5.40$-5.14
Surprise %-1.73%5.99%0.63%-92.05%---

Revenue Forecast

$0 $70M $140M $210M $280M $350M Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$5.20M$2.23M$6.59M$109.16M---
Avg Forecast$6.69M$3.65M$3.17M$3.26M$3.95M$13.75M$153.10M
High Forecast$13.14M$6.60M$4.11M$6.75M$3.98M$30.49M$339.52M
Low Forecast$1.95M$1.67M$2.35M$300.00K$3.92M$1.36M$15.09M
Surprise %-22.29%-38.68%108.07%3246.02%---

Net Income Forecast

$-350M $-270M $-190M $-110M $-30M $50M Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-130.93M$-136.67M$-126.57M$-9.58M---
Avg Forecast$-136.89M$-136.67M$-92.87M$-101.58M$-199.36M$-123.97M$-118.04M
High Forecast$-10.69M$-110.43M$-84.16M$-84.85M$15.33M$21.31M$20.29M
Low Forecast$-308.44M$-139.26M$-101.57M$-118.31M$-230.33M$-320.20M$-304.88M
Surprise %-4.36%-36.29%-90.57%---

IPSC Forecast FAQ

Is Century Therapeutics stock a buy?

Century Therapeutics stock has a consensus rating of Buy, based on 9 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 7 Buy, 2 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Century Therapeutics is a favorable investment for most analysts.

What is Century Therapeutics's price target?

Century Therapeutics's price target, set by 9 Wall Street analysts, averages $3 over the next 12 months. The price target range spans from $2 at the low end to $4 at the high end, suggesting a potential 20.00% change from the previous closing price of $2.5.

How does Century Therapeutics stock forecast compare to its benchmarks?

Century Therapeutics's stock forecast shows a 20.00% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Century Therapeutics over the past three months?

  • March 2026: 20.00% Strong Buy, 60.00% Buy, 20.00% Hold, 0% Sell, 0% Strong Sell.
  • February 2026: 25.00% Strong Buy, 50.00% Buy, 25.00% Hold, 0% Sell, 0% Strong Sell.
  • January 2026: 25.00% Strong Buy, 50.00% Buy, 25.00% Hold, 0% Sell, 0% Strong Sell.

What is Century Therapeutics’s EPS forecast?

Century Therapeutics's average annual EPS forecast for its fiscal year ending in December 2026 is $-1.5, marking a 971.43% increase from the reported $-0.14 in 2025. Estimates for the following years are $-2.09 in 2027, and $-1.99 in 2028.

What is Century Therapeutics’s revenue forecast?

Century Therapeutics's average annual revenue forecast for its fiscal year ending in December 2026 is $3.95M, reflecting a -96.38% decrease from the reported $109.16M in 2025. The forecast for 2027 is $13.75M, and $153.1M for 2028.

What is Century Therapeutics’s net income forecast?

Century Therapeutics's net income forecast for the fiscal year ending in December 2026 stands at $-199M, representing an 1981.00% increase from the reported $-9.58M in 2025. Projections indicate $-124M in 2027, and $-118M in 2028.